Indian Journal of Endocrinology and Metabolism

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 22  |  Issue : 6  |  Page : 728--734

Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India


Jasjeet S Wasir, Ambrish Mithal, Paras Agarwal, Apeksha Mittal 
 Division of Endocrinology and Diabetes, Medanta, The Medicity, Gurugram, Haryana, India

Correspondence Address:
Jasjeet S Wasir
Division of Endocrinology and Diabetes, Medanta, The Medicity, Sector-38, Gurugram, Haryana - 122 001
India

Aims: To evaluate the real-world efficacy, durability, and side-effect profile of once weekly GLP1RA: dulaglutide in Indian type 2 diabetes mellitus (T2DM) patients. Materials and Methods: A retrospective observational study. Data for efficacy (HbA1c and weight), adherence/discontinuation and patient reported side-effects, of 117 patients who were prescribed dulaglutide were analyzed. Results: Final analysis was done on complete data of 74 patients (6 months follow-up), this indicated that dulaglutide is effective (mean-reduction at 6 months of: HbA1c; 0.87% and weight; 3.8 kg). Subjects with a poorer glycemic control (greater HbA1c) or greater weight at initiation had a better fall in HbA1c and weight reduction at the end of the study. The most common side-effects were gastrointestinal (15% nausea and 6% loose motions). Also, 25% (n = 19) of our study subjects discontinued dulaglutide because of gastrointestinal side-effects. Conclusion: Our real-world experience is well aligned to systematic data of the randomized controlled trials (RCTs) regarding the efficacy of dulaglutide in the treatment of T2DM (our study vs. RCTs; HbA1c reduction: 0.87% vs. 0.78% to 1.64%, weight reduction: 3.8 vs. 0.3 to 3 kg). The most common side-effects and reason for discontinuation were gastrointestinal side-effects. Finally, by virtue of their observed benefit, we expect a superior cardiovascular risk-reduction with dulaglutide use in our population.


How to cite this article:
Wasir JS, Mithal A, Agarwal P, Mittal A. Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India.Indian J Endocr Metab 2018;22:728-734


How to cite this URL:
Wasir JS, Mithal A, Agarwal P, Mittal A. Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India. Indian J Endocr Metab [serial online] 2018 [cited 2018 Dec 14 ];22:728-734
Available from: http://www.ijem.in/article.asp?issn=2230-8210;year=2018;volume=22;issue=6;spage=728;epage=734;aulast=Wasir;type=0